Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model

Table 2

MiniPDX drug sensitivity results of the 4 patients.

Number	Chemotherapy regimen	Inhibition rate (1-T/C%)	Weight loss of mice >15%	Source of cancer cells
Patient #1	5, Irinotecan	68	—	Gastroscopic biopsy of gastric cancer
	6, Nab-paclitaxel	47	—
	7, Anlotinib	46	—
	8, Apatinib	52	—
	9, Pyrotinib	55	—
Patient #2	5, Oxaliplatin + capecitabine	20	—	Gastroscopic biopsy of gastric cancer
	6, Oxaliplatin + CF + 5-FU	16	—
	7, Docetaxel + S-1	6	—
	8, S-1	23	—
	9, Apatinib + irinotecan	28	—
Patient #3	5, Irinotecan	80	—	Gastroscopic biopsy of gastric cancer
	6, Nab-paclitaxel		—
	7, Anlotinib		—
	8, Apatinib	81	—
	5, Pyrotinib		—
Patient #4	5, Nab-paclitaxel + S-1		—	Gastroscopic biopsy of gastric cancer
	6, Docetaxel + S-1		—
	7, Irinotecan + apatinib		—
	8, Docetaxel + apatinib	66	—
	9, Fruquintinib + nab-paclitaxel	71	—

1, Notes: Inhibition rate was calculated by 1-T/C% (T/C% = treatment group proliferation rate/control group proliferation rate%). Each regimen was used on MiniPDX models with the same doses. Detailed doses for the MiniPDX models—irinotecan: 50 mg/kg, IP, day 1 and day 5; nab-paclitaxel, 20 mg/kg, IV, day 1–day 5; anlotinib, 3 mg/kg, PO, day 1–day 7; apatinib: 100 mg/kg, PO, day 1–day 7; pyrotinib, 10 mg/kg, PO, day 1–day 7; (oxaliplatin + capecitabine): oxaliplatin (Oxa), 5 mg/kg, IP, day 1 + capecitabine (Cape), 400 mg/kg, PO, day 1–day 7; (oxaliplatin + CF+5-FU): oxaliplatin, 5 mg/kg, IP, day 1 + CF, 50 mg/kg, IP, day 1 + 5-FU, 25 mg/kg, IP, day 1–day 5; (docetaxel + S-1): docetaxel (Doc): 20 mg/kg, IP, day 1 and day 5 + S-1, 10 mg/kg, PO, day 1–day 5; S-1: S-1, 10 mg/kg, PO, day 1–day 5; (irinotecan + apatinib): 50 mg/kg, IP, day 1 and day 5+ 100 mg/kg, PO, day 1–day 7; (nab-paclitaxel + S-1): nab-paclitaxel 20 mg/kg, IV, day 1–day 5 + S-1, 10 mg/kg, PO, day 1–day 5; (docetaxel + apatinib): docetaxel: 20 mg/kg, IP, day 1 and day 5 + apatinib: 100 mg/kg, PO, day 1–day 7; (fruquintinib + nab-paclitaxel): fruquintinib (Fru): 20 mg/kg, PO, day 1–day 7 + 20 mg/kg, IV, day 1–day 5.